Gene Expression Analysis for Tumor Hypoxia Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining tumor hypoxia status are invasive, lack specificity, or require invasive procedures, limiting their effectiveness in identifying patients who would benefit from hypoxia-modifying therapy in cancer treatment.
Innovation Solution
A method involving the measurement of transcriptional expression levels of specific genes, such as ADM and other hypoxia-responsive genes, in cancer samples to assess oxygen status, allowing for the correlation with reference genes and determination of oxygen levels, guiding treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If oxygen sensing electrodes or exogenous hypoxic tracers are used to detect tumor hypoxia, then measurement precision is improved, but ease of operation deteriorates due to mandatory invasive procedures
Solution Approach 1:
The patent replaces mechanical/invasive detection methods (oxygen electrodes, tracer infusions) with a molecular biology-based gene expression analysis system. This substitution eliminates the need for invasive procedures while maintaining hypoxia detection capability through transcriptional markers that reflect oxygen status.
Solution Approach 2:
The patent introduces gene expression markers as intermediary indicators of hypoxia status. Instead of directly measuring oxygen levels or using invasive tracers, the method uses transcriptional responses to oxygen levels as mediators, providing indirect but accurate hypoxia assessment through molecular signatures.
2Ease of operation
If endogenous markers related to HIF-1a cascade are quantified to assess hypoxia, then ease of operation is improved, but measurement precision deteriorates due to inadequate specificity concerning association to hypoxia
Solution Approach 1:
The patent segments the HIF-1a cascade into multiple specific downstream target genes (VEGF, PDGF, TGF-beta, IGF-2, FGF) rather than using a single marker. This segmentation allows detection of hypoxia through multiple independent transcriptional responses, improving specificity while maintaining ease of operation through standardized gene expression analysis.
Solution Approach 2:
The patent creates a composite hypoxia assessment by combining expression levels of multiple genes regulated by HIF-1a. This composite approach integrates multiple molecular indicators to form a more specific and reliable hypoxia signature than any single marker alone.
3Reliability
If hypoxia-modifying agents are administered to all cancer patients, then therapeutic response is improved in hypoxic tumors, but object-generated harmful factors increase due to side effects in non-hypoxic patients
Solution Approach 1:
The patent performs preliminary assessment of hypoxia status through gene expression analysis before administering hypoxia-modifying agents. This preliminary action identifies which patients have hypoxic tumors and would benefit from the therapy, preventing unnecessary treatment and side effects in non-hypoxic patients while ensuring appropriate treatment for hypoxic patients.
Solution Approach 2:
The patent uses gene expression levels of HIF-1a target genes as feedback indicators to guide treatment decisions. The transcriptional response to hypoxia provides feedback information that determines whether hypoxia-modifying therapy should be administered, creating a feedback-controlled treatment strategy that optimizes therapeutic response while minimizing harmful side effects.
Data Source
Figure 1a~1e
Figure 2a~2e
Figure 3a~3d
AI summary
The present invention provides a method for determining the oxygen status of a cancer of an individual. The method comprise determining the transcriptional expression level of ADM (SEQ ID No:1), and/or at least one gene selected from ANKRD37 (SEQ ID NO.: 3), P4HA2 (SEQ ID NO.: 12), NDRG1 (SEQ ID NO: 10), SLC2A1 (SEQ ID NO:15), P4HA1 (SEQ ID NO.: 11), LOX (SEQ ID NO.: 9), C3orf28 (SEQ ID NO.: 6), BNIP3L (SEQ ID NO.: 5), BNIP3 (SEQ ID NO.:4), EGLN3 (SEQ ID NO.: 7), PDK1 (SEQ ID NO.: 13), PFKFB3 (SEQ ID NO.: 14), KCTD11 (SEQ ID NO.: 8), and/or ALDOA (SEQ ID NO.: 2), in a cancer sample. The transcriptional level is then correlated to the transcriptional level to at least one reference gene, and oxygen status10 is then evaluated by comparing the correlated transcription level with a predetermined reference sample comprising cancer cells characterized by a high oxygen level.